Sandostatin

How Does Sandostatin Work?

Sandostatin (octreotide) is a synthetic octapeptide that mimics the active portion of natural somatostatin. It binds primarily to somatostatin receptor subtype 2 (SSTR2), which is the predominant somatostatin receptor on pituitary somatotroph cells and neuroendocrine tumor cells. Binding to SSTR2 activates intracellular signaling pathways that reduce cyclic AMP, decrease calcium entry into cells, and inhibit hormone-releasing vesicle secretion.

In acromegaly, this mechanism suppresses growth hormone (GH) and IGF-1 secretion from pituitary tumor cells, slowing or halting disease progression. In carcinoid syndrome and NETs, octreotide suppresses the secretion of serotonin, histamine, VIP, and other tumor-derived hormones that cause symptoms. It also has a mild antiproliferative effect in SSTR2-positive tumors.

Beyond its primary targets, octreotide suppresses insulin, glucagon, gastrin, TSH, and GI secretions — which explains both its broad therapeutic utility and its side effect profile including glucose dysregulation, hypothyroidism, and gallstone formation.

How Hard Is It to Find Sandostatin in Stock?

Sandostatin has a findability score of 45 out of 100, indicating that it is frequently difficult to find — particularly in LAR (long-acting depot) formulations. As of 2025–2026, the immediate-release injection is available from multiple generic manufacturers (Avet, Fresenius Kabi, Hikma, Sagent), making it relatively accessible. However, the LAR formulations — which most long-term patients rely on — remain supply-constrained.

The shortage is driven by the extraordinary manufacturing complexity of the LAR microsphere formulation and a historically narrow supplier base. The FDA approved Teva's generic LAR in October 2024 and Viatris' generic in 2025, gradually expanding the manufacturer pool. However, supply inconsistency by region and formulation persists. Sandostatin LAR Depot is dispensed exclusively through specialty pharmacies, which further limits access compared to standard retail medications.

If you're having trouble filling your Sandostatin prescription, medfinder can contact pharmacies near you to find which ones have Sandostatin in stock — saving you hours of phone calls.

Who Can Prescribe Sandostatin?

Sandostatin is not a controlled substance, so it can technically be prescribed by any licensed prescriber. However, most insurance plans require prior authorization with documentation from a specialist due to the high cost and specialty-only dispensing requirements. Common payer requirements specify prescribing by or in consultation with an endocrinologist, oncologist, or gastroenterologist.

Typical prescribers by indication:

• Endocrinologists — Primary prescribers for acromegaly and VIPoma
• Oncologists — Primary prescribers for carcinoid syndrome and GEP-NETs, especially NET specialists
• Gastroenterologists — For VIPomas, GEP-NETs, carcinoid syndrome, and off-label GI indications
• Nurse Practitioners / Physician Assistants — May prescribe within specialist practices; often manage stable patients for ongoing refills
• Hepatologists / Critical Care — For acute off-label uses such as esophageal variceal bleeding

Telehealth is limited for initial Sandostatin prescribing because diagnosis requires in-person testing (blood draws, imaging, GH/IGF-1 labs) and LAR injections must be given by a healthcare provider at a clinic. However, established patients with stable disease may use telehealth for follow-up visits, lab result reviews, dose adjustment discussions, and prescription refills.

Is Sandostatin a Controlled Substance?

No. Sandostatin (octreotide) is not a controlled substance and has no DEA schedule classification. It has no known abuse potential or dependency risk. Any licensed prescriber — including MDs, DOs, nurse practitioners, and physician assistants — can prescribe it without DEA authorization.

However, access to Sandostatin — particularly the LAR formulation — is tightly managed through other mechanisms: insurance prior authorization requirements (most plans require specialist prescribing and step therapy), specialty pharmacy dispensing requirements for the LAR formulation, and in some cases, prescriber specialty restrictions on certain insurance plans. These administrative controls mean that while Sandostatin is not legally restricted like a controlled substance, it is not easily obtained without specialist involvement.

Common Side Effects of Sandostatin

The most frequently reported side effects are gastrointestinal, reflecting octreotide's suppression of GI hormones and motility:

• Nausea and vomiting
• Diarrhea or loose stools
• Abdominal pain and cramping
• Flatulence
• Steatorrhea (fatty/oily stools from fat malabsorption)
• Injection site pain and swelling (LAR formulation)
• Headache, dizziness, fatigue

Serious Side Effects

• Gallstones (cholelithiasis) — common with long-term use; may require cholecystectomy
• Pancreatitis
• Bradycardia and cardiac conduction abnormalities (especially with IV use)
• Hypoglycemia or hyperglycemia — blood glucose monitoring required
• Hypothyroidism — TSH and T4 monitoring required
• Vitamin B12 deficiency — periodic monitoring recommended

Final Thoughts on Sandostatin

Sandostatin (octreotide) is a critical medication for patients with acromegaly, carcinoid syndrome, VIPomas, and neuroendocrine tumors. It is highly effective at controlling the hormonal excess that drives these conditions, significantly improving quality of life and, in some cases, slowing disease progression. However, it is one of the more challenging specialty medications to access — requiring specialist prescribing, specialty pharmacy dispensing, insurance prior authorization, and careful monitoring.

Cost is a significant concern, but multiple assistance pathways exist. Commercially insured patients should enroll in the Novartis copay card (up to $15,000/year), which can reduce out-of-pocket costs to $0. Uninsured or underinsured patients should apply for the Novartis Patient Assistance Foundation. Generic octreotide LAR (Teva and Viatris) now provides a more affordable alternative for patients without robust copay support.

Supply remains inconsistent in 2026, particularly for the LAR formulation. If you're struggling to find Sandostatin in stock, medfinder can help locate pharmacies with current availability near you — saving you hours of phone calls and getting you back on your treatment faster.